Lupin Limited

Lupin Limited announced completion of its acquisition of European ophthalmology specialist VISUfarma B.V. from GHO Capital Partners. The deal expands Lupin’s eye‑care portfolio to over 60 branded prod

Lupin Limited completed acquisition of VISUfarma B.V., a European ophthalmology specialty pharma company, from GHO Capital Partners LLP. The deal adds over 60 branded ophthalmic products and commercia

Lupin's wholly owned subsidiary Nanomi B.V. acquires 43.38% minority stake (11,794,497 shares) in Multicare Pharmaceuticals Philippines, Inc. for up to USD 39.6 million. MPPI reported PHP 2,096.6 mill

Lupin's wholly owned Dutch subsidiary Nanomi B.V. completed acquisition of entire share capital of VISUfarma B.V., Netherlands on April 1, 2026. VISUfarma and its wholly owned subsidiaries now become

Lupin received tentative U.S. FDA approval for Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL) ANDA on March 31, 2026. The product is bioequivalent to Merck's Bridion® Injection, used for reversing

Lupin's subsidiary Nanomi B.V. (Netherlands) saw its stake in Multicare Pharmaceuticals Philippines rise from 51% to 56.28% effective March 30, 2026. MPPI bought back 2,813,811 equity shares from exis

Lupin's Operations and Finance Committee allotted 1,35,892 fully paid-up equity shares under ESOP on March 24, 2026. Shares of ₹2 face value each were allotted upon exercise of vested options by emplo

Lupin received tentative U.S. FDA approval for its ANDA for Pitolisant Tablets in 4.45mg and 17.8mg strengths. The product is bioequivalent to Wakix® and will be manufactured at Lupin's Nagpur facilit